Aurora Financial JournalXvivo Perfusion Aktiebolag (XVIVO.ST)
Nasdaq Stockholm · Financial statements, TTM figures and earnings dates
In fiscal year 2023 (ended December 31, 2023), Xvivo Perfusion Aktiebolag reported revenue of SEK 597.5M and net income of SEK 91.8M. Annual financial statements are available for fiscal years 2020 to 2023, taken from the company's ESEF annual reports (IFRS).
Open interactive financials →Key financials
| SEK | FY2023 2023-12-31 | FY2022 2022-12-31 | FY2021 2021-12-31 | FY2020 2020-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | SEK 597.5M | SEK 415.3M | SEK 258.4M | SEK 179.9M |
| Gross profit | SEK 445.1M | SEK 297.0M | SEK 188.3M | SEK 129.7M |
| Operating income | SEK 4.2M | SEK 6.4M | −SEK 18.5M | −SEK 45.7M |
| Net income | SEK 91.8M | SEK 18.4M | SEK 8.2M | −SEK 43.7M |
| Diluted EPS | SEK 3.07 | SEK 0.62 | SEK 0.28 | −SEK 1.60 |
| Cash flow | ||||
| Operating cash flow | SEK 46.3M | SEK 27.9M | −SEK 12.1M | −SEK 12.3M |
| Capital expenditure | SEK 43.0M | SEK 18.2M | SEK 10.2M | SEK 2.6M |
| Free cash flow | SEK 3.3M | SEK 9.7M | −SEK 22.3M | −SEK 14.9M |
| Balance sheet | ||||
| Cash and equivalents | SEK 546.1M | SEK 246.5M | SEK 398.7M | SEK 354.2M |
| Total assets | SEK 2.20B | SEK 1.73B | SEK 1.54B | SEK 1.15B |
| Total liabilities | SEK 250.6M | SEK 302.9M | SEK 257.1M | SEK 141.8M |
| Total debt | SEK 31.4M | SEK 10.0M | SEK 5.7M | SEK 7.2M |
| Shareholders' equity | SEK 1.95B | SEK 1.43B | SEK 1.29B | SEK 1.01B |
TTM = trailing twelve months (balance-sheet items at the latest quarter end). Figures in SEK as reported; per-share data adjusted for stock splits.
Annual reports
More on the interactive page
The full XVIVO.ST page on Aurora Financial Journal includes every fiscal year since the company began filing structured data, income statement, balance sheet and cash flow statement line by line, charts for every measure, valuation multiples (P/E, P/S, P/B), live price charts and the earnings calendar.
Open XVIVO.ST financials →